Heike L. Pahl

Hugstetter Str. 55
Freiburg, BW 79106, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 64 publications

A novel role for transcription factor NFE2 in redox regulation and chemotherapy resistance in acute myeloid leukemia.

A novel role for transcription factor NFE2 in redox regulation and chemotherapy resistance in acute myeloid leukemia.

Journal: Leukemia

Published: February 23, 2026

From image to insight: optimized multiplex staining panel for formalin-fixed, paraffin-embedded mouse bone marrow enables spatial profiling of the hematopoietic niche.

From image to insight: optimized multiplex staining panel for formalin-fixed, paraffin-embedded mouse bone marrow enables spatial profiling of the hematopoietic niche.

Journal: Experimental hematology

Published: January 15, 2026

NFE2 Truncation Mutants Protect Wild-Type NFE2 from ITCH-Dependent Degradation.

NFE2 Truncation Mutants Protect Wild-Type NFE2 from ITCH-Dependent Degradation.

Journal: International journal of molecular sciences

Published: November 10, 2025

Response to PD-1 inhibition in MMRd/MSS pancreatic ductal adenocarcinoma: the relevance of parallel testing.

Response to PD-1 inhibition in MMRd/MSS pancreatic ductal adenocarcinoma: the relevance of parallel testing.

Journal: Journal of cancer research and clinical oncology

Published: July 13, 2025

Lysine-specific demethylase 1 regulates hematopoietic stem cell expansion and myeloid cell differentiation.

Lysine-specific demethylase 1 regulates hematopoietic stem cell expansion and myeloid cell differentiation.

Journal: Cell death & disease

Published: June 12, 2025

Final Results From a Large, Non-Interventional, Phase 4 Study of Ruxolitinib for the Treatment of Myelofibrosis in Clinical Routine.

Final Results From a Large, Non-Interventional, Phase 4 Study of Ruxolitinib for the Treatment of Myelofibrosis in Clinical Routine.

Journal: European journal of haematology

Published: February 25, 2025

Malignant JAK-signaling: at the interface of inflammation and malignant transformation.

Malignant JAK-signaling: at the interface of inflammation and malignant transformation.

Journal: Leukemia

Published: January 02, 2025

Oncogenic Calreticulin Induces Immune Escape by Stimulating TGFβ Expression and Regulatory T-cell Expansion in the Bone Marrow Microenvironment.

Oncogenic Calreticulin Induces Immune Escape by Stimulating TGFβ Expression and Regulatory T-cell Expansion in the Bone Marrow Microenvironment.

Journal: Cancer research

Published: November 10, 2023

Oncogene-induced TIM-3 ligand expression dictates susceptibility to anti-TIM-3 therapy in mice.

Oncogene-induced TIM-3 ligand expression dictates susceptibility to anti-TIM-3 therapy in mice.

Journal: The Journal of clinical investigation

Published: November 08, 2023

Real-world analysis of ruxolitinib in myelofibrosis: interim results focusing on patients who were naïve to JAK inhibitor therapy treated within the JAKoMo non-interventional, phase IV trial.

Real-world analysis of ruxolitinib in myelofibrosis: interim results focusing on patients who were naïve to JAK inhibitor therapy treated within the JAKoMo non-interventional, phase IV trial.

Journal: Annals of hematology

Published: July 28, 2023

GPRC5C drives branched-chain amino acid metabolism in leukemogenesis.

GPRC5C drives branched-chain amino acid metabolism in leukemogenesis.

Journal: Blood advances

Published: April 13, 2023

The histone demethylase JMJD2C constitutes a novel NFE2 target gene that is required for the survival of JAK2V617F mutated cells.

The histone demethylase JMJD2C constitutes a novel NFE2 target gene that is required for the survival of JAK2V617F mutated cells.

Journal: Leukemia

Published: September 23, 2022

Showing 1-12 of 64

Last Updated: 09/26/2026